Trials / Completed

CompletedNCT00346242

Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events

Status: Completed
Phase: Phase 4
Study type: Interventional
Enrollment: 60 (planned)

Sponsor: Novartis Pharmaceuticals · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The evaluation of efficacy is performed by laboratory monitoring of bone density and resorption markers and clinical monitoring of bone density improvement. This is a prospective, randomized, parallel group, single blind study of one year treatment with zoledronic acid every 6 months as compared to one year treatment with zoledronic acid every 3 months and to placebo every 3 months in patients with hemoglobin syndromes and risk of skeletal complications.

Conditions

Thalassemia

Interventions

Type	Name	Description
DRUG	Zoledronic Acid

Timeline

Start date: 2004-03-01
Primary completion: 2006-03-01
First posted: 2006-06-29
Last updated: 2012-05-01

Locations

1 site across 1 country: Greece

Source: ClinicalTrials.gov record NCT00346242. Inclusion in this directory is not an endorsement.